Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.

Annals of the rheumatic diseases（2023）

引用 11|浏览40

暂无评分

摘要

Dual inhibition of IL-17A and IL-17F with bimekizumab resulted in significant and rapid improvements in efficacy outcomes vs placebo and was well tolerated in patients with nr-axSpA and r-axSpA.

查看译文

关键词

Autoimmune Diseases,Biological Therapy,Cytokines,Inflammation,Spondylitis, Ankylosing

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要